Human butyrylcholinesterase - Altimmune

Drug Profile

Human butyrylcholinesterase - Altimmune

Alternative Names: NEX 91; Protexia; rBChE; rBChE bioscavenger; Recombinant human butyrylcholinesterase

Latest Information Update: 05 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAthene
  • Class Antidotes; Butyrates; Cholinesterases
  • Mechanism of Action Scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Poisoning

Highest Development Phases

  • No development reported Alzheimer's disease; Poisoning

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 04 May 2017 Altimmune merged with PharmAthene and the combined entity was renamed as Altimmune
  • 08 Sep 2014 Human butyrylcholinesterase - PharmAthene is available for licensing as of 08 Sep 2014. http://www.pharmathene.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top